DNLI 8-K: Press Release for Quarter Ended June 30, 2025 Attached as Exhibit 99.1

Rhea-AI Filing Summary

Denali Therapeutics Inc. furnished a Form 8-K reporting that on August 11, 2025 the company issued a press release announcing its financial results for the quarter ended June 30, 2025. The press release is attached as Exhibit 99.1 and the filing includes an Inline XBRL cover page as Exhibit 104. The filing states that the information is furnished and not deemed to be "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference except by specific reference. The report identifies the registrant as Denali Therapeutics Inc. (DNLI), incorporated in Delaware and listed on the Nasdaq Global Select Market.

Positive

• Press release announcing Q2 2025 results was furnished and attached as Exhibit 99.1
• Inline XBRL cover page (Exhibit 104) was included, supporting data tagging and accessibility
• Timely disclosure with an executed signature by the Chief Operating and Financial Officer

Negative

• No financial figures or performance metrics are contained in this Form 8-K; the underlying press release text is not presented here
• The filing states the information is furnished, not filed, limiting incorporation by reference under the securities acts

Insights

Financial Analyst

TL;DR: Routine 8-K furnishing a Q2 2025 earnings press release; the filing itself contains no financial figures.

The company furnished a press release reporting results for the quarter ended June 30, 2025 and attached it as Exhibit 99.1, with an Inline XBRL cover page as Exhibit 104. This Form 8-K is a standard disclosure action that informs the market the release exists; it does not, by itself, present numbers or performance metrics. Impact assessment: not impactful in isolation because the filing furnishes but does not embed financial data or analysis.

Corporate Governance Expert

TL;DR: Procedural filing evidencing timely disclosure; legal notice clarifies the release is furnished, not formally filed under Section 18.

The Form 8-K documents the attachment of a press release as Exhibit 99.1 and includes the registrant's signature by the Chief Operating and Financial Officer. The filing explicitly states the furnished information is not deemed "filed" under Section 18 and is not incorporated by reference, which is a standard legal protection for issuers. Impact assessment: not impactful for governance or statutory obligations beyond routine disclosure.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001714899FALSE00017148992025-08-112025-08-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

August 11, 2025

Denali Therapeutics Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-38311

46-3872213

(State or other jurisdiction of

(Commission

(I.R.S. Employer

incorporation)

File Number)

Identification No.)

161 Oyster Point Blvd.

South San Francisco, California 94080

(Address of principal executive offices, including zip code)

(650) 866-8547

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last reports)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol (s)			Name of each exchange on which registered
Common Stock, par value $0.01 per share			DNLI			Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company			☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02     Results of Operations and Financial Condition.

On August 11, 2025, Denali Therapeutics Inc. (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2025. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01    Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
99.1						Press Release dated August 11 2025.
104						Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						DENALI THERAPEUTICS INC.
Date:			August 11, 2025			By:			/s/ Alexander O. Schuth
									Alexander O. Schuth, M.D.
									Chief Operating and Financial Officer

FAQ

What did Denali Therapeutics (DNLI) file on August 11, 2025?

Denali furnished a Form 8-K reporting it issued a press release announcing its financial results for the quarter ended June 30, 2025; the press release is attached as Exhibit 99.1.

Does the 8-K include the company’s Q2 2025 financial statements and figures?

No. The Form 8-K states a press release announcing results was furnished, but the 8-K text does not include the financial figures themselves.

What exhibits were filed with this 8-K for DNLI?

Exhibit 99.1 (press release dated August 11, 2025) and Exhibit 104 (Cover Page Interactive Data File formatted as Inline XBRL) are listed.

Is the information in this 8-K considered "filed" under the Exchange Act?

No. The filing explicitly states the information furnished in Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act.

Who signed the Form 8-K for Denali Therapeutics?

The Form 8-K is signed by Alexander O. Schuth, M.D., Chief Operating and Financial Officer, dated August 11, 2025.